Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Lactobacillus rhamnosus GMNL-464** is a specific probiotic strain isolated from the human intestine, deposited at CGMCC (China General Microbiological Culture Collection) under deposit number CCTCC No. M2015610. It is a Gram-positive, rod-shaped, non-spore-forming, non-motile, facultative anaerobic bacterium with optimal growth at 25-45°C and pH 4.0-10.0, featuring a partial 16S rDNA sequence (SEQ ID NO: 3) confirming its identity as L. rhamnosus. This strain, often used heat-inactivated (90-121°C for 15-30 minutes), inhibits adhesion of oral pathogens such as Fusobacterium nucleatum (ATCC 25586) to gingival cells and demonstrates synergistic effects in combinations with L. paracasei GMNL-143 and L. helveticus GMNL-164 for preventing bacterial adhesion in the oral cavity. It is incorporated into probiotic toothpastes for gingivitis management and shows coaggregation with oral bacteria, reducing pro-inflammatory cytokines while promoting anti-inflammatory responses and inhibiting pathogens like Streptococcus mutans.[1][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lactobacillus rhamnosus GMNL-464.